Search

Displaying results 1111 - 1120 of 10000 in total
  1. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022. … Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success.

  2. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050 … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].

    Categories: Drugs Used in Diabetes, DPP-IV Inhibitors
  3. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. … [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]

    Synonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE
  4. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.

  5. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    lines of systemic therapy, including a BTK inhibitor. … Sonrotoclax is a selective, potent, small-molecule inhibitor of BCL-2, an antiapoptotic protein overexpressed in B-cell malignancies.

    Synonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- yl
  6. Drug

    Ademetionine

    go.drugbank.com/drugs/DB00118
    ApprovedInvestigationalNutraceutical

    Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. … It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)

    Mixtures: HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETLİ ŞİŞE, HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETSİZ ŞİŞE
  7. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626]. … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Sofosbuvir as first line therapy

    Mixtures: MYHEP ALLProducts: I-HEP SOBOVIR
  8. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel is indicated as a fifth line treatment of adult patients with relapsed or refractory multiple myeloma. … [A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.

  9. Drug

    Butenafine

    go.drugbank.com/drugs/DB01091
    Approved

    In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes. … Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols.

    Synonyms: N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine, (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine
  10. Drug

    Olive oil

    go.drugbank.com/drugs/DB09567
    ApprovedInvestigational

    Used as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].

    Mixtures: CLINOLEIC %20 IV İNFÜZYONLUK LİPİD EMÜLSİYON, 100 ML, CLINOLEIC %20 IV İNFÜZYONLUK LİPİD EMÜLSİYON, 250 MLProducts: Intensive Treatment Bodyoil for Mommy To Be All Skin